MXPA04007434A - Treatment of male sexual dysfunction. - Google Patents

Treatment of male sexual dysfunction.

Info

Publication number
MXPA04007434A
MXPA04007434A MXPA04007434A MXPA04007434A MXPA04007434A MX PA04007434 A MXPA04007434 A MX PA04007434A MX PA04007434 A MXPA04007434 A MX PA04007434A MX PA04007434 A MXPA04007434 A MX PA04007434A MX PA04007434 A MXPA04007434 A MX PA04007434A
Authority
MX
Mexico
Prior art keywords
treatment
sexual dysfunction
male sexual
oxytocin antagonist
selective oxytocin
Prior art date
Application number
MXPA04007434A
Other languages
Spanish (es)
Inventor
Christopher Peter Wayman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MXPA04007434A publication Critical patent/MXPA04007434A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A composition comprising a selective oxytocin antagonist for use in the treatment and/or prevention of a male ejaculatory disorder; which selective oxytocin antagonist is optionally admixed witha a pharmaceutically acceptable carrier, diluent or excipient.
MXPA04007434A 2002-01-31 2003-01-20 Treatment of male sexual dysfunction. MXPA04007434A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0202282.0A GB0202282D0 (en) 2002-01-31 2002-01-31 Treatment of male sexual dysfunction
PCT/IB2003/000140 WO2003064402A1 (en) 2002-01-31 2003-01-20 Treatment of male sexual dysfunction

Publications (1)

Publication Number Publication Date
MXPA04007434A true MXPA04007434A (en) 2004-10-11

Family

ID=9930155

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04007434A MXPA04007434A (en) 2002-01-31 2003-01-20 Treatment of male sexual dysfunction.

Country Status (16)

Country Link
EP (1) EP1470115A1 (en)
JP (3) JP2005525321A (en)
KR (2) KR100829262B1 (en)
CN (1) CN100500658C (en)
AU (1) AU2003201471B2 (en)
BR (1) BR0307337A (en)
CA (1) CA2474590A1 (en)
GB (1) GB0202282D0 (en)
HK (1) HK1073109A1 (en)
IL (2) IL162822A0 (en)
MX (1) MXPA04007434A (en)
NZ (1) NZ546408A (en)
PL (1) PL371415A1 (en)
TW (1) TW200302732A (en)
WO (1) WO2003064402A1 (en)
ZA (1) ZA200405208B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3646871A1 (en) * 2018-10-30 2020-05-06 SEROJAC PME Handels GmbH Treatment and prevention of premature ejaculation (pe)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
AU690534B2 (en) * 1992-12-23 1998-04-30 Merck & Co., Inc. Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
EP0614894A1 (en) * 1993-03-12 1994-09-14 Merck & Co. Inc. Process for the synthesis of substituted amide derivatives of piperazinylcamphorsulfonyl oxytocin antagonists
GB0007884D0 (en) 2000-03-31 2000-05-17 Pfizer Ltd Diphenyl ether compounds useful in therapy
US20020028799A1 (en) * 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction

Also Published As

Publication number Publication date
HK1073109A1 (en) 2005-09-23
PL371415A1 (en) 2005-06-13
EP1470115A1 (en) 2004-10-27
KR20080011232A (en) 2008-01-31
IL162822A (en) 2010-11-30
AU2003201471B2 (en) 2009-03-26
BR0307337A (en) 2004-12-07
JP2005525321A (en) 2005-08-25
NZ546408A (en) 2007-10-26
CN1625553A (en) 2005-06-08
JP2010209075A (en) 2010-09-24
ZA200405208B (en) 2005-08-31
KR20040079958A (en) 2004-09-16
IL162822A0 (en) 2005-11-20
GB0202282D0 (en) 2002-03-20
JP2013151511A (en) 2013-08-08
WO2003064402A1 (en) 2003-08-07
TW200302732A (en) 2003-08-16
CN100500658C (en) 2009-06-17
KR100829262B1 (en) 2008-05-13
CA2474590A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
SG148202A1 (en) Quinazolinone compounds as anticancer agents
MXPA03010790A (en) Nitrogen-containing bicyclic heterocycles for use as antibacterials.
UA84141C2 (en) Use of iват inhibitor in treatment and/or prophylaxis of constipation
IL176452A0 (en) Effervescent oral opiate dosage form
MXPA05013142A (en) Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents.
AP2001002125A0 (en) Controlled-rease pharmaceutical formulations.
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
TW200505454A (en) Heteroaryl-fused pyrimidinyl compounds as anticancer agents
GB0101577D0 (en) Compounds
UA84271C2 (en) Formate salt of o-desmethyl-venlafaxine
MXPA04000586A (en) Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor.
WO2004005324A3 (en) Peptide composition for treatment of sexual dysfunction
GB0426313D0 (en) Therapeutic agents
PL367065A1 (en) Use of osteopontin for the treatment and/or prevention of neurologic diseases
MY137620A (en) Therapeutic treatment
MY128896A (en) Pharmaceutical combinations
EP1448194A4 (en) Apomorphine-containing dosage form for ameliorating male erectile dysfunction
AU2001285318A1 (en) Use of an aldosterone receptor antagonist to improve cognitive function
EP1441718A4 (en) Carbinols for the treatment of neuropathic dysfunction
IL162154A0 (en) Prostagandin composition for the treatment of erectile dysfunction
PL1603584T3 (en) Aplidine for multiple myeloma treatment
MXPA04007434A (en) Treatment of male sexual dysfunction.
HRP20030892A2 (en) Prevention of addiction in pain management
NZ525774A (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
IL166273A0 (en) Methods of treatment of male erectile dysfunction

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights